Table 1 Clinical and histopathologic characteristics of the study population.
Clinical characteristics | Ascites PEDF (μg/ml) | Serum PEDF (μg/ml) | ||||
|---|---|---|---|---|---|---|
<16.6 (n = 14) | >16.6 (n = 14) | P | <16.6 (n = 9) | >16.6 (n = 14) | P | |
Age, mean ± SD | 61.6 ± 9.93 | 63.86 ± 8.96 | 0.54 | 60.11 ± 11.8 | 63.57 ± 10.1 | 0.50 |
FIGO stage | 0.48 | 0.54 | ||||
I/II | 0 | 2 (14) | 2 (22) | 1 (7) | ||
III/IV | 14 (100) | 12 (86) | 7 (78) | 13 (93) | ||
LN metastasis | >0.99 | >0.99 | ||||
Yes | 2 (14) | 2 (14) | 1 (11) | 1 (7) | ||
No | 12 (86) | 12 (86) | 8 (89) | 13 (93) | ||
Distant metastasis | 0.38 | 0.54 | ||||
Yes | 5 (36) | 2 (14) | 2 (22) | 1 (7) | ||
No | 9 (64) | 12 (86) | 7 (78) | 13 (93) | ||
Recurrence within 2 years(Stage II/III)a | 0.07 | 0.043 | ||||
Yes | 2 (22) | 7 (70) | 1 (17) | 9 (75) | ||
No | 7 (78) | 3 (30) | 5 (83) | 3 (25) | ||
